Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.72 |
| ▸ | MMP2 | P08253 | 4/20 | 0.72 |
| ▸ | MMP9 | P14780 | 4/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | NAMPT | P43490 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | JUN | P05412 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25722352 | 0.86 | NPC1 (0.59) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL13352237 | 0.85 | MMP1 (0.78) | MMP1MMP2MMP9EGFRNPC1 | |
| N-O-Tolylcinnamamide SCHEMBL15902545 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRNPC1 | |
| N-O-Tolylcinnamamide SCHEMBL29844171 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRNPC1 | |
| N-O-Tolylcinnamamide SCHEMBL2593756 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRNPC1 | |
| N-O-Tolylcinnamamide SCHEMBL2593754 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRNPC1 | |
| SCHEMBL25722340 | 0.84 | HDAC1 (0.77) | NAMPTNPC1RAB9AKDM4EHDAC1 | |
| SCHEMBL10054789 | 0.84 | NAMPT (0.54) | MMP1MMP2MMP9EGFRNAMPT | |
| SCHEMBL25725290 | 0.84 | NAMPT (0.57) | EGFRNAMPTMAPK1 | |
| SCHEMBL25725288 | 0.83 | NAMPT (0.54) | NAMPTNPC1RAB9AKDM4EJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | SALL4, GLI2, GLI1 | MMP1 4680/4885MMP2 2852/4885MMP9 3877/4885 |
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | MMP1 19/4885MMP2 88/4885MMP9 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.